Cara Therapeutics (NASDAQ: NASDAQ:CARA ) is undergoing a significant transformation as it announces strategic shifts in its operations, including substantial layoffs and a departure at the executive level. The biopharmaceutical company is redirecting its focus towards its late-stage notalgia paresthetica program, necessitating a withdrawal from advanced chronic...
Cara Therapeutics is back on the strong resistance line that has been tested 4 times. Only once, in June 2017, was this briefly broken after FDA breakthrough therapy designation.
CR845 reduces itching in patients with chronic liver insufficiency. This brought in June 2018 3 large pharmaceutical companies on the plan, who wanted to market this product against once...
